Staccato Prochlorperazine in Migraine (in Clinic)
| Status: | Completed |
|---|---|
| Conditions: | Migraine Headaches, Migraine Headaches |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 1/27/2018 |
| Start Date: | March 2005 |
| End Date: | October 2005 |
A Multi-center, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of StaccatoTM Prochlorperazine for Inhalation in Patients With Migraine Headache
Development of Staccato Prochlorperazine for the treatment of migraine headache.
Inclusion Criteria:
- Subjects who have migraine headache with or without aura (diagnosis according to
International Headache Society guidelines) for at least 6 months, who have been pain
free for at least 48 hours since the end of their last migraine attack, who have a
pain rating of Moderate or Severe prior to dosing.
Exclusion Criteria:
- Subjects who have taken any other migraine or pain medication within 48 hours of
randomization, with a history of allergy or intolerance to phenothiazines and related
drugs, or are considered by the investigator, for any reason, to be an unsuitable
candidate for receiving prochlorperazine, or unable to use the inhalation device, must
be excluded.
We found this trial at
1
site
Click here to add this to my saved trials
